


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1. (currently amended) ~~Use of the compounds of the following formula (I):~~ A method for the treatment of neurodegenerative diseases comprising administering an effective amount of a compound of formula (I):




wherein X represents OH, (C<sub>1-5</sub>)alkoxy, NH<sub>2</sub>, NH-C<sub>1-5</sub>-alkyl, or N(C<sub>1-5</sub> alkyl)<sub>2</sub>;

R<sub>1</sub> is a residue derived from any of the amino acids Phe, Tyr, Trp, or Pro, each of which may optionally be substituted by a (C<sub>1-5</sub>) alkoxy group, a (C<sub>1-5</sub>) alkyl group or a halogen atom, and Ala, Val, Leu, or Ile;

R<sub>2</sub> is a residue which is derived from any of the amino acids Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp, Leu ~~and~~ or Asn;

R<sub>3</sub> and R<sub>4</sub> independently represent H, OH, (C<sub>1-5</sub>) alkyl, or (C<sub>1-5</sub>)alkoxy, provided that R<sub>3</sub> and R<sub>4</sub> are not both OH or (C<sub>1-5</sub>)alkoxy;

R<sub>5</sub> represents H, OH, (C<sub>1-5</sub>) alkyl or (C<sub>1-5</sub>)alkoxy;  
and wherein R<sub>0</sub> represents a group of the formula



wherein Y represents -CO-, -CH<sub>2</sub>CO-, -CH<sub>2</sub>CH<sub>2</sub>CO-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CO-, -CH=CH-CO or -OCH<sub>2</sub>CO-, and wherein Z represents a halogen atom, a trifluormethyl group, (C<sub>1-4</sub>) alkoxy group, (C<sub>1-4</sub>) alkyl group; or wherein two neighboring substituents may form a (C<sub>1-3</sub>) alkylendioxy group; and wherein n is 0 or an integer of from 1 to 5;  
or pharmaceutically acceptable salts thereof;

~~for the preparation of a medicament useful in the treatment of neurodegenerative diseases.~~

2. (currently amended) The use method according to claim 1, wherein R<sub>1</sub> is a residue derived from any of the amino acids Phe, Tyr, Trp, each of which may optionally be substituted by a (C<sub>1-5</sub>) alkoxy group, a (C<sub>1-5</sub>) alkyl group or a halogen atom, or a residue derived from the amino acid Ile.

3. (currently amended) The use method according to claim 2, wherein R<sub>1</sub> is a residue derived from Phe which may optionally be substituted by a (C<sub>1-5</sub>) alkoxy group, a (C<sub>1-5</sub>) alkyl group or a halogen atom.

4. (currently amended) The use method according to ~~any of the preceding claims~~ claim 1, wherein X is (C<sub>1-5</sub>) alkoxy, NH<sub>2</sub>, NH-C<sub>1-5</sub> alkyl, or N(C<sub>1-5</sub> alkyl)<sub>2</sub>.

5. (currently amended) The use method according to ~~any of the preceding claims~~ claim 1, wherein R<sub>2</sub> is a residue derived from the amino acid Gly or Ile.

6. (currently amended) The use method according to ~~any of the preceding claims~~ claim 1, wherein R<sub>0</sub> is a cinnamoyl moiety.

7. (currently amended) The ~~use~~ method according to ~~any of the preceding claims~~ claim 1, wherein the compound of formula (I) is cinnamoyl-glycyl-L-phenylalanyl-L-prolinamide, cinnamoyl-isoleucyl-phenylalanyl-L-proline ethylamide, cinnamoyl-isoleucyl-isoleucyl-prolineamide, or a pharmaceutically acceptable salt thereof.